Knopp Biosciences receives FDA Orphan Drug designation for dexpramipexole
Knopp Biosciences announced the FDA has granted Orphan Drug Designation to dexpramipexole, its oral drug candidate for the treatment of hypereosinophilic syndrome. HES is a rare and often incapacitating disorder with limited treatment options. April 24, 2019